LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline
2024年7月30日 - 10:00PM
ビジネスワイヤ(英語)
LTZ Therapeutics, an immunotherapy-focused biotech company,
today announced the completion of the company’s Series A financing
of over $20 million, to advance the development of its Myeloid
Engager pipeline to treat cancer and autoimmune diseases. This
round was led by new investor Lapam Capital and includes new
investment participation from GL Ventures. In addition, the company
has received continued investment from K2 Venture Partners and
Shunwei Capital. The closing of this round brings LTZ’s total
funding to approximately $50 million since the company was founded
in 2022.
Proceeds from the financing will be used to accelerate
development of LTZ’s pipeline, supporting the company’s
Investigational New Drug (IND) process, initiating the Phase 1
clinical study of LTZ’s lead asset LTZ-301 as well as the
IND-enabling work of its second asset, LTZ-232. The company will
also use the new capital to further advance other programs in
discovery and to expand its team.
“This round represents an important step forward in the
development of our novel Myeloid Engager Platform for cancer and
other conditions with unmet medical needs,” said Robert Li, Ph.D.,
Founder and CEO of LTZ. “At the heart of our approach is the fusion
of reverse translational science with a deep understanding of tumor
microenvironment (TME) biology, especially myeloid biology. We’ve
made significant progress this past year, not only validating the
company’s platform in various preclinical test systems including
cancer patient-derived organoid models, but also advancing our lead
asset LTZ-301 from discovery to an IND-enabling stage. We are
thankful for the ongoing support of our scientific team, advisory
board and our syndicate of investors, making all of our
accomplishments possible.”
Macrophages appear to be one of the most prevalent immune cell
populations in TME of various hematologic and solid tumors.
Therefore, effectively engaging and activating macrophages to kill
cancer cells represents significant therapeutic potential for
patients. Based on reverse translational research to inform new
discoveries and the emerging myeloid biology of TME in a broad
range of cancer types, LTZ is developing its own novel Myeloid
Engager Platform to primarily enhance the phagocytic function of
monocytes and macrophages to foster anti-tumor immunity.
“LTZ comprises a highly skilled and passionate team that brings
together a unique complement of expertise,” said Zhihua Yu,
Founding Partner at Lapam Capital. “We are excited about the
reverse translational approach LTZ is taking to maximize the
drugability of their assets. LTZ’s Myeloid Engager Platform and
their pipeline have the potential to greatly impact the future of
immunotherapy development, aiming to rebalance the immune system
and improve patient outcomes. The preclinical results thus far
carry promising clinical benefits and suggest applicability of
LTZ’s model for a wide spectrum of cancer indications (liquid and
solid) and autoimmune diseases, where the unmet need is incredibly
high.”
About LTZ
LTZ Therapeutics is an immunotherapy-focused biotech company
pursuing the development of novel therapies, with the company’s
novel Myeloid Engager Platform, to improve clinical outcomes in
patients with cancer and autoimmune diseases. With main operations
in Redwood City, California and Shenzhen, China as well as a team
out of Heidelberg Germany, LTZ is dedicated to developing
immunotherapies capable of overcoming resistance and boosting
anti-tumor immunity based on reverse translational science and
emerging disease biology of tumor microenvironment. For more
information, please visit
https://www.ltztherapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730426200/en/
Media Contact: Betsy Levy betsy.levy@ltztherapeutics.com
415-377-3112